Find out about TECregen's, a Basel-based company developing novel biologics designed to rejuvenate the thymus, “thymopoietics ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

As 2025 ends, delve into some biotech feel-good stories where the right treatment meets the right patient, almost feeling ...

The OECD recently published an update on key biotechnology indicators, an opportunity for us to delve into the top-performing countries in the field. With the highest number of active biotech ...

Last year, we took a look at the biotech trends that we thought would shape 2024. Now, as we enter the new year, the biotech industry is continuing to evolve at a rapid pace, and 2025 is shaping up to ...

Unlike other industries, biotech startups often require substantial initial capital to support extensive research and development (R&D), clinical trials, and regulatory approvals before generating any ...

Asking whether China is the future of the biotech industry might seem counterintuitive, considering the current biotech geopolitical context. If you haven’t followed this series of events, a ...

Once a booming field, bustling with innovation and money driving that innovation, the cell and gene therapy sector is now struggling to fuel therapeutic growth to bring medicines to patients. It doesn ...

Antibody therapies constitute a vast global market: currently valued at over $250 billion, the market for antibodies is expected to exceed $850 billion worldwide by 2032. Driving forces behind this ...

In the life sciences industry, collaboration is paramount in the field of research, to help move ideas and programs forward through the various stages. Here, experts explain the importance of research ...

In June, AstraZeneca once again turned to the Chinese company CSPC Pharmaceuticals, with whom it initially entered into an exclusive license agreement in October 2024 for an early-stage cardiovascular ...

The need for change in Novo Nordisk’s operations became irrefutably clear in July, when the company named its new CEO, Maziar Mike Doustdar, and simultaneously issued a profit warning for its ...